REDWOOD CITY, Calif., April 2, 2026
Revolution Medicines has announced the initiation of patient dosing in its global Phase 3 RASolute 303 trial, evaluating daraxonrasib (RMC-6236) as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (PDAC), a highly aggressive cancer with extremely poor survival outcomes. The trial represents a major advancement in the development of RAS(ON) inhibitors, targeting one of the most critical oncogenic drivers in cancer biology, and aims to address a significant unmet need in pancreatic cancer treatment, where current therapies offer limited efficacy.
Phase 3 Trial Targets First-Line Treatment Opportunity
The RASolute 303 trial is a randomized, open-label, global Phase 3 study designed to evaluate daraxonrasib as monotherapy and in combination with chemotherapy (gemcitabine and nab-paclitaxel) compared to standard-of-care chemotherapy alone in patients with previously untreated metastatic PDAC. The study will assess key endpoints including progression-free survival (PFS) and overall survival (OS), along with secondary measures such as tumor response, safety, tolerability, and patient-reported outcomes.
Notably, the trial is enrolling patients irrespective of RAS mutation subtype, reflecting the therapy’s broad-spectrum activity against multiple oncogenic RAS variants. This design underscores a strategic effort to expand targeted therapy into earlier lines of treatment, where clinical benefit may be maximized and patient outcomes significantly improved.
RAS(ON) Inhibition Offers Novel Mechanism in Oncology
Advertisement
Daraxonrasib is an oral, multi-selective RAS(ON) inhibitor that works by blocking active RAS signaling, preventing interaction with downstream effectors that drive tumor growth and survival. Unlike earlier approaches that struggled to target RAS directly, this next-generation therapy is designed to inhibit both wild-type and mutant RAS proteins, offering a comprehensive strategy to suppress oncogenic signaling pathways. Given that over 90% of pancreatic cancers are driven by RAS mutations, this mechanism represents a highly relevant and potentially transformative therapeutic approach.
The initiation of multiple Phase 3 trials across cancers such as non-small cell lung cancer and colorectal cancer further highlights the broad applicability and clinical potential of RAS(ON) inhibition as a cornerstone in precision oncology.
Addressing High Mortality and Unmet Medical Need
Pancreatic cancer remains one of the deadliest malignancies, with approximately 60,000 new cases and 50,000 deaths annually in the United States, and a five-year survival rate of just around 3% in metastatic disease. Due to late diagnosis and resistance to standard therapies, nearly 80% of patients are diagnosed at advanced stages, limiting treatment options and survival prospects.
The development of daraxonrasib as a first-line therapy aims to shift the treatment paradigm by introducing a targeted, mechanism-driven approach earlier in disease progression, potentially improving both survival outcomes and quality of life. Revolution Medicines’ broader pipeline of RAS(ON) inhibitors targeting specific mutations such as G12C, G12D, and G12V further reinforces its leadership in advancing next-generation targeted cancer therapies.
With the launch of the RASolute 303 trial, Revolution Medicines accelerates the clinical development of a promising targeted therapy, positioning daraxonrasib as a potential breakthrough in the treatment of RAS-driven cancers and offering renewed hope for patients facing one of the most challenging and lethal forms of cancer.
Source: Revolution Medicines press release
